Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B
Ubals, Maria (Hospital Universitari Vall d'Hebron)
Bosch-Nicolau, Pau (Hospital Universitari Vall d'Hebron)
Sánchez-Montalvá, Adrián (Hospital Universitari Vall d'Hebron)
Salvador, Fernando (Hospital Universitari Vall d'Hebron)
Aparicio, Gloria (Hospital Universitari Vall d'Hebron)
Sulleiro Igual, Elena (Hospital Universitari Vall d'Hebron)
Silgado, Aroa (Hospital Universitari Vall d'Hebron)
Soriano-Arandes, Antoni (Hospital Universitari Vall d'Hebron)
Espiau, María (Hospital Universitari Vall d'Hebron)
Ferrer, Berta (Hospital Universitari Vall d'Hebron)
Pou, Diana (Hospital Universitari Vall d'Hebron)
Treviño Maruri, Begoña (Hospital Universitari Vall d'Hebron)
Molina Romero, Israel (Hospital Universitari Vall d'Hebron)
García-Patos Briones, Vicente (Hospital Universitari Vall d'Hebron)
Universitat Autònoma de Barcelona

Data:	2021
Resum:	There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. We performed a retrospective study in Vall d'Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Complex cutaneous leishmaniasis ; Cutaneous leishmaniasis ; Leishmania ; Liposomal amphotericin B ; Systemic therapy
Publicat a:	Pathogens, Vol. 10 (september 2021) , ISSN 2076-0817

DOI: 10.3390/pathogens10101253
PMID: 34684202

9 p, 922.3 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats